Edition:
United Kingdom

Melinta Therapeutics Inc (MLNT.OQ)

MLNT.OQ on NASDAQ Stock Exchange Global Select Market

2.64USD
24 May 2019
Change (% chg)

$-0.17 (-6.05%)
Prev Close
$2.81
Open
$2.82
Day's High
$2.82
Day's Low
$2.61
Volume
30,996
Avg. Vol
94,729
52-wk High
$45.88
52-wk Low
$2.61

Latest Key Developments (Source: Significant Developments)

Melinta Therapeutics Q4 Loss Per Share $3.94
Wednesday, 13 Mar 2019 

Melinta Therapeutics Inc ::MELINTA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $3.94.Q4 EARNINGS PER SHARE ESTIMATE $-4.33 -- REFINITIV IBES DATA.Q4 REVENUE $96.4 MILLION.Q4 REVENUE ESTIMATE $16.9 MILLION -- REFINITIV IBES DATA.SEES 2019 NET PRODUCT SALES OF APPROXIMATELY $65 MILLION.NET PRODUCT SALES OF $14.6 MILLION FOR Q4 OF 2018.SEES 2019 GROSS MARGIN OF APPROXIMATELY 55%, INCLUDING INTANGIBLE ASSETS AMORTIZATION.SEES 2019 OPERATING EXPENSES OF APPROXIMATELY $140 MILLION.  Full Article

John Johnson Agrees To Become Permanent CEO Of Melinta Therapeutics
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Melinta Therapeutics Inc ::JOHN H. JOHNSON AGREES TO BECOME PERMANENT CHIEF EXECUTIVE OFFICER OF MELINTA THERAPEUTICS.MELINTA THERAPEUTICS INC - JOHNSON SERVED AS INTERIM CEO OF COMPANY SINCE OCTOBER 22, 2018.MELINTA THERAPEUTICS - JOHNSON TO BECOME CEO SUBJECT TO TERMS OF AN EMPLOYMENT CONTRACT, CLOSE OF COMMITMENT FOR UP TO $135 MILLION CREDIT FACILITY.  Full Article

Melinta Therapeutics Inc - Reaffirms Product Sales And Cost Savings Guidance
Wednesday, 19 Dec 2018 

Melinta Therapeutics Inc ::MELINTA THERAPEUTICS ANNOUNCES COMMITMENT FOR NEW CREDIT FACILITY OF UP TO $135 MILLION.MELINTA THERAPEUTICS INC SAYS ADJOURNED ITS SPECIAL MEETING OF STOCKHOLDERS SCHEDULED FOR DECEMBER 20, 2018 TO A DATE TO BE DETERMINED LATER.MELINTA THERAPEUTICS INC - REAFFIRMS PRODUCT SALES AND COST SAVINGS GUIDANCE.MELINTA THERAPEUTICS INC - CREDIT FACILITY HAS OPTION TO BE CONVERTED INTO PREFERRED SHARES.MELINTA THERAPEUTICS INC - BELIEVE NEW CREDIT FACILITY FROM VATERA WILL TAKE CO TO APPROACHING CASH FLOW BREAKEVEN.MELINTA THERAPEUTICS INC - ONCE COMPLETED, CONFIDENT CASH INFUSION WILL PROVIDE CO WITH LIQUIDITY TO FUND BUSINESS WELL INTO 2020.MELINTA THERAPEUTICS INC - UPON EXECUTION, FINAL LOAN AGREEMENT WILL REPLACE PREVIOUSLY ANNOUNCED PURCHASE AGREEMENT BETWEEN MELINTA AND VATERA.  Full Article

Melinta Therapeutics Q3 Loss Per Share $0.50
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Melinta Therapeutics Inc ::MELINTA THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.50.Q3 EARNINGS PER SHARE VIEW $-0.94 -- THOMSON REUTERS I/B/E/S.MELINTA THERAPEUTICS INC - IMPLEMENTED COST REDUCTION INITIATIVES TO REDUCE OPERATING EXPENSES BY MORE THAN $50 MILLION IN 2019.MELINTA THERAPEUTICS INC - QTRLY TOTAL REVENUE $34.1 MILLION VERSUS $3.2 MILLION.  Full Article

Melinta Therapeutics Announces Appointment Of Interim Chief Executive Officer
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Melinta Therapeutics Inc ::MELINTA THERAPEUTICS ANNOUNCES APPOINTMENT OF JOHN H. JOHNSON AS INTERIM CHIEF EXECUTIVE OFFICER.MELINTA THERAPEUTICS INC - JOHNSON SUCCEEDS DAN WECHSLER.MELINTA THERAPEUTICS INC - JOHN H. JOHNSON APPOINTED AS INTERIM CEO EFFECTIVE IMMEDIATELY.  Full Article

Melinta Therapeutics And Menarini Group Enter Commercial Agreement
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS AND MENARINI GROUP ENTER COMMERCIAL AGREEMENT FOR VABOMERE™ (MEROPENEM AND VABORBACTAM), ORBACTIV® (ORITAVANCIN) AND MINOCIN® (MINOCYCLINE) FOR INJECTION IN 68 COUNTRIES.MELINTA THERAPEUTICS, INC. - TOTAL CONSIDERATION OF UP TO $265 MILLION (INCLUDING POTENTIAL ROYALTIES).MELINTA THERAPEUTICS- WILL RECEIVE UPFRONT LICENSING FEE, ADDITIONAL APPROVAL AND SALES-BASED MILESTONE PAYMENTS, AND POTENTIAL ROYALTY PAYMENTS.MELINTA THERAPEUTICS, INC. - EXPANDS ON EXISTING COMMERCIAL AND CO-DEVELOPMENT AGREEMENT FOR BAXDELA(®) (DELAFLOXACIN).MELINTA THERAPEUTICS - TO MAINTAIN RIGHTS FOR VABOMERE, ORBACTIV AND MINOCIN FOR INJECTION IN U.S..  Full Article

Melinta Therapeutics Prices Public Offering Of 22.0 Mln Shares At $5/Share
Thursday, 24 May 2018 

May 23 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 22.0 MILLION COMMON SHARES PRICED AT $5.00PER SHARE.  Full Article

Melinta Therapeutics Announces Proposed Offering Of Common Stock
Monday, 21 May 2018 

May 21 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.MELINTA THERAPEUTICS - COMMENCED UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK TO RAISE AGGREGATE PROCEEDS OF APPROXIMATELY $75 MILLION.MELINTA THERAPEUTICS - INTENDS TO USE PROCEEDS FROM PROPOSED SALE OF ITS SHARES TO INVEST IN PORTFOLIO OF ANTIBIOTICS, AMONG OTHERS.  Full Article

Melinta Therapeutics Says ‍Partner Commenced New Program For Topical Formulation Of Radezolid, In Preparation For Submitting IND Application To FDA
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS - ‍PARTNER COMMENCED NEW PROGRAM FOR A TOPICAL FORMULATION OF RADEZOLID, IN PREPARATION FOR SUBMITTING AN IND APPLICATION TO FDA.  Full Article

Melinta Therapeutics Files For Resale Of Up To 3.3 Mln Shares By Selling Stockholder
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING.  Full Article